While PTP1b inhibitor Sorafenib was able to decrease PTP1B activity in HCC, PTP1B overexpression impaired the sensitivity of sorafenib both in vitro and in vivo [32]. This evidence concerns the gene PTPN1 and hepatocellular carcinoma.